Login to Your Account



Zytiga Phase III Halt Raises Stakes in Prostate Cancer

By Marie Powers
Staff Writer

Friday, March 9, 2012
Shares of Medivation Inc. and Dendreon Corp. took opposite trajectories Thursday after Janssen Research & Development LLC unblinded its Phase III study of Zytiga (abiraterone acetate) plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) who had not received chemotherapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription